â Home
Johnson Johnson 
Pharma / Pharmaceuticals and Healthcare
Press Releases
| Date | Press release |
|---|---|
| 2025-04-30 13:42:00 | Fda Approves Johnson & Johnsonâs Imaavytm (nipocalimab-aahu) A New Treatment For Myasthenia Gravis (mg), Offering Hope For Families First and only fcrn blocker approved in anti-achr and anti-musk antibody positive adults and pediatric gmg patients aged 12 and older. first and only fcrn blocker approved in anti-achr and anti-musk antibody positive adults and pediatric gmg patients aged 12 and older. |
| 2025-04-30 08:29:00 | Johnson & Johnson Receives Fda Approval For Imaavy⢠(nipocalimab-aahu), A New Fcrn Blocker Offering Long-lasting Disease Control In The Broadest Population Of People Living With Generalized Myasthenia Gravis (gmg) First and only fcrn blocker approved in anti-achr and anti-musk antibody positive adults and pediatric gmg patients aged 12 and older  imaavy delivered rapid and substantial reduction in immunoglobulin g (igg) levels, one of the root causes of gmg, in both the adult and pediatric pivotal studies          gmg patients taking imaavy demonstrated 20 months of lasting disease control and symptom relief in the pivotal vivacity-mg3 study and ongoing open-label extension (ole) spring house, pa. , april 30, 2025 /prnewswire/ -- johnson & johnson (nyse: jnj) today announced that the u.s. food and drug administration (fda) has approved imaavy⢠(nipocalimab-aahu), a human fcrn-blocking monoclonal antibody, for the treatment of generalized myasthenia gravis (gmg). |
| 2025-04-28 16:22:00 | Johnson & Johnson To Participate In The Bernsteinâs 41st Annual Strategic Decisions Conference New brunswick, n.j.--(business wire)--johnson & johnson (nyse: jnj) will present at the bernsteinâs 41st annual strategic decisions conference on wednesday, may 28th, 2025. management will participate in a fireside chat at 10:00 a.m. eastern time. a live audio webcast of the presentation will be accessible through johnson & johnsonâs investor relations website at www.investor.jnj.com. an archived edition of the session will be available later that day. the audio webcast replay will be a. |
| 2025-04-26 14:00:00 | Johnson & Johnsonâs Tar-200 Monotherapy Achieves High Disease-free Survival Of More Than 80 Percent In Bcg-unresponsive, High-risk Papillary Nmibc First results from sunrise-1 (cohort 4) show strong disease-free survival rates across high-grade papillary tumors, demonstrating the potential for bladder preservation with 94 percent of patients avoiding radical cystectomy 95 percent progression-free survival rate at 9-months signals the promise of tar-200 in this high-risk patient population las vegas , april 26, 2025 /prnewswire/ -- johnson & johnson (nyse: jnj) today announced first results from cohort 4 of the phase 2b sunrise-1 study evaluating tar-200âan intravesical gemcitabine releasing systemâfor patients with certain types of bladder cancer. these first results show the promise of tar-200 in this patient population with more than an 80 percent disease-free survival (dfs) rate without the need for reinduction and 94 percent of patients able to preserve their bladder. |
| 2025-04-26 13:50:00 | Johnson & Johnsonâs Tar-200 Monotherapy Demonstrates Highest Complete Response Rate Reported To Date With Sustained Clinical Benefits In Patients With Certain Types Of Bladder Cancer Phase 2b sunrise-1 study shows more than 82 percent of patients achieved complete response (cr) with more than half of responders remaining cancer-free at one year after cr1 |
© 2024 - 2025 InsightfulValue.com. All rights reserved.
Legal